On Nov 05, major Wall Street analysts update their ratings for $Verona Pharma (VRNA.US)$, with price targets ranging from $42 to $64.
Wells Fargo analyst Tiago Fauth maintains with a buy rating, and maintains the target price at $64.
Jefferies analyst Andrew Tsai maintains with a buy rating, and adjusts the target price from $38 to $45.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $34 to $51.
Truist Financial analyst Joon Lee maintains with a buy rating.
CCORF analyst Edward Nash maintains with a buy rating, and adjusts the target price from $37 to $44.
Furthermore, according to the comprehensive report, the opinions of $Verona Pharma (VRNA.US)$'s main analysts recently are as follows:
The company's sales in October were reported to surpass those in Q3, even before the acquisition of a permanent J-code and the potential inclusion in the GOLD guidelines. This not only indicates a promising near-term launch trajectory but also substantially lessens the risk of a launch 'fizzle'.
Verona Pharma's Q3 sales outperformed expectations, with a reported $5.6M surpassing the projected $2M. This performance, coupled with a novel mechanism of action, management's optimistic outlook for Q4 and beyond into 2025, and favorable evaluations, leads to the anticipation of increased sales momentum. This bolsters the prospects for what could become a leading COPD treatment.
Here are the latest investment ratings and price targets for $Verona Pharma (VRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$維羅納製藥 (VRNA.US)$的評級，目標價介於42美元至64美元。
富國集團分析師Tiago Fauth維持買入評級，維持目標價64美元。
富瑞集團分析師Andrew Tsai維持買入評級，並將目標價從38美元上調至45美元。
BTIG分析師Thomas Shrader維持買入評級，並將目標價從34美元上調至51美元。
儲億銀行分析師Joon Lee維持買入評級。
CCORF分析師Edward Nash維持買入評級，並將目標價從37美元上調至44美元。
此外，綜合報道，$維羅納製藥 (VRNA.US)$近期主要分析師觀點如下：
該公司十月份的銷售額據報超過了第三季度的銷售額，甚至在獲得永久J代碼以及有望被納入黃金指南之前。這不僅表明了一個有前景的近期推出軌跡，而且大大降低了推出時的風險。
維羅納製藥的第三季度銷售額超出預期，報道的560萬美元超過了預計的200萬美元。這種表現，加上一種新穎的作用機制、管理層對第四季度及2025年以及之後的樂觀前景以及積極評價，導致了對增加銷售勢頭的期待。這增強了成爲主要COPD治療的前景。
以下爲今日6位分析師對$維羅納製藥 (VRNA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
